Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
Katrina J. Church, the Senior Vice President and Chief Compliance Officer at Bioventus Inc. (NASDAQ:BVS), recently sold a portion of her holdings in the company. According to a recent SEC filing, Church sold 1,283 shares of Bioventus Class A Common Stock on April 11, 2025. The shares were sold at a weighted average price of $7.57, totaling approximately $9,712. The stock, which has gained over 71% in the past year according to InvestingPro data, currently trades at $7.74, slightly above the transaction price. With a market capitalization of $511 million, Bioventus appears slightly undervalued based on comprehensive analysis available through InvestingPro’s Fair Value model.
The sale was conducted as part of a standing 10b5-1 instruction, a pre-established trading plan often used by executives to manage the sale of their stocks. Following this transaction, Church continues to own 55,557 shares of Bioventus. The shares were sold to cover taxes upon the vesting of restricted stock units, as noted in the filing. Investors tracking this development should note that Bioventus is scheduled to report earnings in 28 days, on May 13, 2025. InvestingPro analysis reveals 8 additional key insights about the company’s financial health and future prospects, available to subscribers.
In other recent news, Bioventus Inc. reported its fourth-quarter 2024 earnings, surpassing revenue forecasts with $154 million, a 14% increase year-over-year, compared to the expected $145.16 million. The company also announced a full-year adjusted EBITDA of $109 million, marking a 23% rise from the previous year. This growth was primarily driven by strong performances in its Surgical Solutions and Pain Treatments segments. Additionally, Bioventus made significant strides in reducing its debt, paying down nearly $50 million, which has enhanced its financial health. Looking forward, Bioventus projects net sales between $560 million and $570 million for 2025, indicating organic growth of 6-8%. Canaccord Genuity maintained a Buy rating on Bioventus, with a $15 price target, citing the company’s strategic focus on growth and profitability under CEO Rob Claypoole’s leadership. The firm’s strategy includes expanding its sales force and increasing market awareness, with plans to accelerate free cash flow generation by 2025. These recent developments highlight Bioventus’s commitment to achieving its financial goals and strengthening its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.